Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ákos Szabó has a total of 59 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Psychometric properties of four FACE-Q Aesthetics scales in patients planning and undergoing minimally invasive facial cosmetic procedures

    by Eszter Mercédesz Müller, Anna Nikl, Máté Krebs, Ákos Szabó, Péter Holló, Valentin Brodszky, Fanni Rencz, Lajos Vince Kemény

    Objectives: This study aimed to assess aspects of validity of four FACE-Q Aesthetics scales in a sample of patients undergoing and planning facial minimally invasive cosmetic procedures (MICPs), such as botulinum toxin, lip augmentation and soft tissue augmentation treatments. Methods: In 2023, a cross-sectional survey included 210 Hungarian women who had undergone and 147 planning facial MICPs, with similar mean ages Respondents completed four FACE-Q scales (Aging Appraisal, Appearance Distress, Early Life Impact and Age VAS), EQ-5D-5L, Rosenberg Self-Esteem Scale (RSES) and the Brief Fear of Negative Evaluation Scale-Straightforward Items (BFNE-S). Comprehensibility, ceiling/floor effects, structural validity (principal component analysis, confirmatory factor analysis), internal consistency, and construct validity (convergent, divergent, known-group validity) of the four FACE-Q scales were assessed. Results: All FACE-Q scales, except the Age VAS, showed a ceiling effect (20–28%). Appearance Distress showed strong convergent validity with RSES (r = 0.742), BFNE-S (r = − 0.702), and EQ-5D-5L anxiety/depression (r = − 0.519). Aging Appraisal and Appearance Distress scales were unidimensional, whereas Early Life Impact Scale had a three-factor structure. All four FACE-Q scales were able to differentiate between known groups of patients based on self-esteem, fear of negative evaluation and acceptance of bodily appearance. Women who had undergone procedures reported higher Aging Appraisal (72.9 vs. 63.3) and Appearance Distress (77.1 vs. 68.4) scores and felt younger (− 5.0 vs. − 2.8 years) than those planning them ( p < 0.001 for all). Conclusions: Our findings provide initial support for the validity of the four FACE-Q scales in MICP populations, but further validation (e.g. assessment of responsiveness and test–retest reliability) is needed.

  • Open Access

    Comparing the measurement properties of the EQ-5D-Y-3L and EQ-5D-3L in a general population sample of adults

    by Anna Nikl, Valentin Brodszky, Ákos Szabó, Fanni Rencz

    Objectives: EQ-5D has separate three-level versions for children/adolescents (EQ-5D-Y-3L) and adults (EQ-5D-3L), assessing the same five dimensions of health-related quality of life (HRQoL) using age-appropriate language. Little is known about how differences in wording affect self-reported HRQoL assessments. This study aimed to compare the measurement properties of the EQ-5D-Y-3L and EQ-5D-3L in an adult general population sample. Methods: A cross-sectional study was conducted in a Hungarian adult general population sample representative by age and gender ( n = 1,196). Measurement properties, including ceiling, floor, informativity, agreement (Kendall’s tau) and known-groups validity (effect sizes) based on self-perceived health and chronic conditions were compared across instruments. Results: EQ-5D-Y-3L and EQ-5D-3L yielded 85 and 47 unique health states, respectively. Identical health profiles were reported by 59.0%. Overall ceiling was lower using the EQ-5D-Y-3L (34.8%) than the EQ-5D-3L (46.8%), with the largest dimension-level difference for EQ-5D-Y-3L worried/sad/unhappy (56.8%) vs. EQ-5D-3L anxiety/depression (71.6%). Relative informativity was higher for all EQ-5D-Y-3L dimensions (0.20–0.75) than EQ-5D-3L (0.18–0.66). Agreement was the weakest for worried/sad/unhappy vs. anxiety/depression (0.636) and the strongest for mobility (0.841). Both instruments showed medium to large effect sizes across known-groups based on level sum scores (EQ-5D-Y-3L: 0.820–2.454; EQ-5D-3L: 0.820–2.696) and index values (EQ-5D-Y-3L: 0.754–2.362; EQ-5D-3L: 0.747–2.365), with EQ-5D-Y-3L showing higher discriminatory power in 62–69% of known groups. Conclusion: Notable differences emerged between EQ-5D-Y-3L and EQ-5D-3L in an adult general population sample, especially in the mental health dimension, suggesting that transitions between these instruments should be treated cautiously. The EQ-5D-Y-3L may offer advantages in detecting variations in mental health, even in adult populations.


  • Open Access

    The Impact of Homelessness on Lung Cancer Survival and Healthcare Utilization in the Hungarian Universal Healthcare System

    by Daniel Heilig, Ákos Szabó, Petra Fadgyas-Freyler, Judit Simon

    Differences in the lifestyle and health-service-seeking behavior of persons experiencing homelessness (PEH) are well known. However, a comprehensive estimation of the resulting healthcare utilization differences and health outcome impacts are so far under-researched, especially at the national level. We aim to close this gap of evidence for lung cancer within the Hungarian universal healthcare system. We analyzed lung cancer-related information for the PEH population in the Hungarian national central health insurance register dataset and a matched control population between 2015 and 2021. In this period, 11,857 people were registered as homeless for the majority of at least one year. To capture the effect of homelessness, we created a categorical “homelessness length index” (HLI) according to the proportion of time an individual experienced homelessness during the investigation period (HLI 0: 0; HLI 1: >0–1/3; HLI 2: >1/3–2/3; HLI 3: >2/3). PEH individuals were matched 1:5 with a non-PEH control sample adjusted for age, sex and region. We conducted Kaplan–Meier survival analysis and Cox proportional hazards (CPH) regression adjusted for age, sex, HLI and average lung cancer-related healthcare costs. Our final analysis sample consisted of 641 patients (233 PEH, 408 control) who were newly diagnosed with lung cancer during the observation period. The lung cancer prevalence in the PEH group was 1.97% as opposed to 0.69% in the control group. The Kaplan–Meier curve showed lower average survival times for the PEH group, compared to the control group. Lung cancer associated costs between diagnosis and death/censoring were substantially different with average per patient cumulative costs of EUR 3668 in the PEH group compared to EUR 6827 in the control group (2018 prices). This translated to an average 47% lower annual lung cancer-related healthcare cost per PEH patient. CPH analysis showed that after disease severity, the degree of time spent in homelessness had the most significant effect on mortality, with a HR of 1.47 associated with both HLI 2 and 3 (95% CI: 1.08–2.00 and 1.01–2.14, respectively). We find that in Hungary, homelessness is associated with a much higher lung cancer burden linked to a three-times-higher prevalence, lower overall survival and almost 50% lower annualized disease-specific healthcare costs. Worse outcomes are mainly driven by long-term homelessness. Results could not be further refined according to lifestyle-related factors due to data availability limitations.


  • Open Access

    Comparing EQ-5D-5L, PROPr, SF-6D and TTO utilities in patients with chronic skin diseases

    by Ákos Szabó, Valentin Brodszky, Fanni Rencz

    Objectives: We aim to compare the measurement properties of three indirect (EQ-5D-5L, PROPr, SF-6D) and one direct (time trade-off, TTO) utility assessment methods in patients with chronic skin diseases. Methods: 120 patients with physician-diagnosed chronic skin diseases (psoriasis 39%, atopic dermatitis 27%, acne 19%) completed a cross-sectional survey. Respondents completed the EQ-5D-5L, PROMIS-29+2 and SF-36v1 questionnaires and a 10-year TTO task for own current health. Utilities were computed using the US value sets. Ceiling, convergent and known-group validity were compared across the utilities derived with these four methods. Known-groups were defined based on general, physical and mental health. The agreement between utilities was assessed using intraclass correlation coefficients (ICC). Results: Mean utilities for the EQ-5D-5L, PROPr, SF-6D and TTO were 0.79, 0.47, 0.76 and 0.89. In corresponding order, the ceiling was 28%, 0%, 2% and 65%. The SF-6D showed excellent agreement with the EQ-5D-5L (ICC = 0.770). PROPr demonstrated poor agreement with the EQ-5D-5L (ICC = 0.381) and fair with SF-6D utilities (ICC = 0.445). TTO utilities showed poor agreement with indirectly assessed utilities (ICC = 0.058–0.242). The EQ-5D-5L better discriminated between known groups of general and physical health, while the SF-6D and PROPr outperformed the EQ-5D-5L for mental health problems. Conclusion: There is a great variability in utilities across the four methods in patients with chronic skin conditions. The EQ-5D-5L, despite its higher ceiling, appears to be the most efficient in discriminating between patient groups for physical health aspects. Our findings inform the choice of instrument for quality-adjusted life year calculations in cost-utility analyses.


  • Open Access

    Content validity of the EQ-5D-5L with skin irritation and self-confidence bolt-ons in patients with atopic dermatitis: a qualitative think-aloud study

    by Eszter Szlávicz, Ákos Szabó, Ágnes Kinyó, Anita Szeiffert, Tamás Bancsók, Valentin Brodszky, Rolland Gyulai, Fanni Rencz

    Objectives: Two bolt-on dimensions (skin irritation, self-confidence) have been developed for the EQ-5D-5L to improve its content validity and responsiveness in psoriasis. However, the two bolt-ons are not strictly psoriasis-specific and are potentially relevant in other skin conditions. This study aims to explore the content validity of the EQ-5D-5L with two bolt-ons in patients with atopic dermatitis (AD). Methods: In 2021–2022, qualitative, semi-structured interviews were conducted with 20 adult AD patients at a university dermatology clinic in Hungary. We aimed for a heterogeneous sample in terms of age, gender, education and disease severity. Patients completed the EQ-5D-5L with two bolt-ons using a think-aloud protocol. Probing questions were posed to investigate item relevance, potential conceptual overlaps, missing concepts and the appropriateness of the recall period. Interview transcripts were subjected to thematic analysis. Results: The EQ-5D-5L with the two bolt-ons covered the most important aspects of health-related quality of life in AD patients. Most patients found both the skin irritation and self-confidence bolt-ons relevant. Fifteen potential missing concepts were identified, but only two (social relationships, judgement by others) were identified by more than one patient. A smaller conceptual overlap was found between the skin irritation and pain/discomfort dimensions in 7 patients (35%). Half the patients expressed a preference for a recall period of 1 week rather than of ‘today’. Conclusions: The EQ-5D-5L with skin irritation and self-confidence bolt-ons showed good relevance, comprehensiveness and comprehensibility in patients with AD. However, in terms of comprehensiveness, social relationships and judgement by others (stigma) may be missing from the questionnaire.


  • Open Access

    Real-World Experience with Cemiplimab Treatment for Advanced Cutaneous Squamous Cell Carcinoma—A Retrospective Single-Center Study

    by Daniella Kuzmanovszki, Norbert Kiss, Béla Tóth, Veronika Tóth, József Szakonyi, Kende Lőrincz, Judit Hársing, Enikő Kuroli, Eleonóra Imrédi, Tünde Kerner, et al.

    Background: The systemic treatment of advanced cutaneous squamous cell carcinoma (cSCC) has seen significant developments in recent years. The anti-PD1 inhibitor cemiplimab has demonstrated efficacy in clinical trials, but real-world data are still limited. Here, we aimed to evaluate the efficacy and the safety of cemiplimab in a real-world clinical setting. Methods: A retrospective analysis was carried out for all patients who received at least two doses of cemiplimab at our department between February 2020 and January 2023. Progression-free survival (PFS), overall survival (OS), the objective response rate (ORR), the disease control rate (DCR) and adverse events (AEs) were evaluated. Results: Twenty-five patients were included with a median age of 78 (65–82) years. The median treatment duration was 48 (16–72) weeks. Five (20%) patients were immunocompromised. Sixteen patients (64%) developed AEs, including 36% serious AEs (SAEs) of grade ≥ 3. Six patients (24%) were withdrawn from treatment due to the occurrence of AEs. Among the 25 patients, 52% showed an objective response (3 complete and 10 partial responses), 76% had controlled disease and 24% experienced progression. Among the five immunocompromised patients, the ORR was 60%, while the DCR was 80%. Conclusions: This retrospective real-world study revealed that locally advanced or metastatic cSCC could be effectively treated with cemiplimab even in elderly, polymorbid and immunocompromised patients.


  • Open Access

    Anti-PD-1 Monotherapy in Advanced Melanoma—Real-World Data from a 77-Month-Long Retrospective Observational Study

    by Daniella Kuzmanovszki, Norbert Kiss, Béla Tóth, Tünde Kerner, Veronika Tóth, József Szakonyi, Kende Lőrincz, Judit Hársing, Eleonóra Imrédi, Alexa Pfund, et al.

    Real-world evidence plays an important role in the assessment of efficacy and safety of novel therapies. The increasing use of immune checkpoint inhibitors (ICIs) in patients with advanced melanoma has led to notably improved clinical outcomes, while they are also associated with immune-related adverse events (irAEs). The majority of the available data are based on clinical trials, where the investigated subjects often do not adequately represent the general patient population of the everyday practice. Although there is a niche of objective biomarkers for the future treatment response of ICIs, certain studies suggest that irAEs may be predictive. The aim of this study was to carry out a retrospective analysis of treatment data from patients with advanced melanoma, treated with a single anti-PD-1 agent (pembrolizumab or nivolumab) during a 77-month-long period. Treatment efficacy and occurrence of adverse events were analyzed to identify potential predictive markers. Primary and secondary endpoints were the overall survival (OS) and progression-free survival (PFS). In our cohort, we demonstrated that the occurrence of more than one irAE showed a correlation with response to PD-1 ICI therapy and improved the OS and PFS. Our study suggests, that the grade of toxicity of the irAE may affect the survival rate.


  • Open Access

    General and Skin-Specific Health-Related Quality of Life in Patients With Atopic Dermatitis Before and During the COVID-19 Pandemic

    by Kamilla Koszorú, Krisztina Hajdu, Valentin Brodszky, Ákos Msc Szabó, Júlia Borza, Katalin Bodai, Györgyi Pónyai, Andrea Dsc Szegedi, Miklós Sárdy, Fanni Rencz

    Background Few studies have investigated health-related quality of life (HRQoL) in patients with atopic dermatitis (AD) during the COVID-19 pandemic. Objectives The objectives of this study were to compare HRQoL in adult AD patients before and during the pandemic and to assess measurement performance of 4 HRQoL measures. Methods Between 2018 and 2021, a multicenter, cross-sectional survey was conducted, involving 218 adult AD patients. Health-related quality of life outcomes included the EQ-5D-5L, Skindex-16, Dermatology Life Quality Index (DLQI), and DLQI-Relevant (DLQI-R). Severity was measured using objective SCORing Atopic Dermatitis, Eczema Area and Severity Index, and Investigator Global Assessment. Results The mean ± SD EQ-5D-5L utility, Skindex-16, DLQI, and DLQI-R scores were 0.82 ± 0.22, 56.84 ± 27.46, 13.44 ± 8.46, and 13.76 ± 8.60, respectively. The patients reported more problems during the pandemic (P < 0.05) regarding pain/discomfort (odds ratio [OR], 1.78), worrying (OR, 1.89), concerns about persistence/reoccurrence of disease (OR, 1.88), and social relationships (OR, 1.69). The HRQoL outcomes showed strong correlations with each other (range of rs, |0.69| to |0.99|). The Skindex-16, DLQI, and DLQI-R were able to discriminate between severity groups with large (η2 = 0.20–0.23), whereas the EQ-5D-5L with moderate effect sizes (η2 = 0.08–0.11). Conclusions Atopic dermatitis patients experienced significantly more problems in some areas of HRQoL during the pandemic. The EQ-5D-5L, Skindex-16, DLQI, and DLQI-R demonstrated good convergent and known-group validity and can be suitable instruments for HRQoL assessment in clinical and research settings.


  • Közgáz diáktudós - Kötődés és bizalom: Válogatás a BCE Közgáz Campus tudományos diákköri munkáiból

    by Bálint György Bognár, Dávid Csábráki, Tamás Csordás, Marcell Granát, Szabolcs Hadászi, Ariel Zoltán Mitev, Szonja Ondrik, Ákos Szabó, Ágnes Wimmer

    Könyvünk a 2010-ben indított Közgáz Diáktudós sorozat tizennegyedik kötete, a sorozatban publikált tanulmányok és a szerzők száma is jóval száz fölött jár. Évről évre a Budapesti Corvinus Egyetem Tudományos Diákköri (TDK) konferenciáján eredményesen szereplő hallgatókat kérünk fel arra, hogy TDK-munkáik alapján készítsenek önálló, az eredeti dolgozatnál rövidebb, összefoglaló tanulmányokat, melyek betekintést adnak kutatásukba, egyfajta hallgatói tudományos tükörként, s kedvcsinálóként is a kutatásban kezdő hallgatótársaik számára. Az itt publikált munkák igen széles spektrumot fednek le mind tartalmukat, mind az alkalmazott kutatási, elemzési módszereket tekintve. Még színesebb a kép, ha fellapozzuk (akár virtuálisan, a BCE könyvtárának honlapján megtalálható elektronikus példányokban) a korábbi köteteket, vagy tallózunk az egyetemi könyvtári repozitóriumba feltöltött munkák között, esetleg az Országos Tudományos Diákköri Tanács (OTDT) honlapján a korábbi eredmények és rezümékötetek között nézelődünk. Ez a sokszínűség is jelzi, hogy kutatni, TDK-t írni szinte bármilyen témában, kérdésről lehet. Az itt publikált és a TDK konferenciákon évről évre, az országos TDK konferenciákon (OTDK) kétévente bemutatott munkákat összekötő legfőbb kapocs a kíváncsiság, a (tudományos) érdeklődés, mely kutatásra csábítja a résztvevőket. Az erre épülő felfedező, elemző munkát mentoraik, konzulenseik, a felkészítésben közreműködő oktatók támogatják, ennek eredménye évről évre országosan több ezer, egyetemünkön több száz tudományos diákköri munka. Kötetünk bevezető tanulmányában kitérünk arra, hogy miért is érdemes TDKzni, milyen szerepe lehet a TDK-nak a kutatói kíváncsiságtól a tudományos pályáig (vagy más sikeres szakmai pályafutásig) vezető úton, egyben egy rövid áttekintést is adunk a Budapesti Corvinus Egyetem TDK-tevékenységéről és eredményeiről. Ezt követi az idei sikeres TDK-zók munkáiból készült válogatás, összesen hat tanulmány, majd a kötet végén a Budapesti Corvinus Egyetem 2021. évi Tudományos Diákköri Konferenciáján díjazott dolgozatok listája, illetve az ETDT által az évben odaítélt hallgatói és oktatói kiválósági díjak bemutatása kap helyet. A tizennegyedik diáktudós kötetbe bekerült tanulmányok is változatos képet mutatnak mind a témákat, mind pedig az alkalmazott módszereket tekintve (...)

  • Open Access

    A comparative study on the measurement properties of Dermatology Life Quality Index (DLQI), DLQI‐Relevant and Skindex‐16*

    by Á. Szabó, V. Brodszky, F. Rencz

    Background Dermatology Life Quality Index (DLQI) and Skindex-16 are among the most commonly used dermatology-specific health-related quality of life (HRQoL) instruments. DLQI has two common scoring methods, the original and the DLQI-R modification. Head-to-head comparisons on measurement properties of DLQI, DLQI-R and Skindex-16 are currently lacking. Objectives We aim to compare measurement properties of DLQI, DLQI-R and Skindex-16. Methods We analysed data of 618 patients with self-reported physician-diagnosed dermatological conditions from a cross-sectional survey carried out in early 2020 in Hungary. DLQI, DLQI-R and Skindex-16 were compared in terms of ceiling and floor effects, informativity, convergent and known-group validity. Results Mean DLQI, DLQI-R and Skindex-16 total scores were 3.76±5.03, 4.11±5.34 and 29.36±26.62, respectively. Among patients with a DLQI/DLQI-R total score of zero, 64% reported problems on Skindex-16. Overall, 23-38% of patients with a ‘not relevant’ responses on DLQI items 3 (shopping/home/gardening), 7 (working/studying), 8 (interpersonal problems) and 9 (sexual difficulties) reported problems on their corresponding Skindex-16 items. Average relative informativity (Shannon’s evenness index) was the highest for Skindex-16 (0.85), followed by DLQI-R (0.66) and DLQI (0.54). DLQI, DLQI-R and Skindex-16 demonstrated similar convergent validity. DLQI was able to better discriminate between known groups of patients based on overall skin-related HRQoL impairment, while DLQI-R and Skindex-16 performed better with respect to self-perceived health status. Conclusion Skindex-16 seems to be more sensitive to capture mild impairment in HRQoL than DLQI/DLQI-R. Our findings help to fully understand the difference between DLQI, DLQI-R and Skindex-16 and support the informed choice of instrument for clinical and research purposes.